港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

486.060

+3.7030.77%

漲家數：19

跌家數：7

平家數：7

市盈率：- -

高：489.931

開：482.072

低：481.405

收：482.357

成交量：3,223.40萬

成交額：7.62億

市值：3,089.83億

流通市值：2,746.02億

資料載入中...

總覽新聞資訊

2026國談第五日：商保創新藥目錄價格協商開始多家藥企攜核藥、CAR-T新藥等重磅藥物進場

我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參

每日经济新闻

中藥創新從「經驗方」走到「數據方」

港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」

諾華製藥(NVS)股票9月8日開盤下跌12.63%：釋放什麼信號？

TradingKey中文

同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份

和鉑醫藥-B(02142)：HBM9378/WIN378治療哮喘的 II期臨床取得陽性的中期結果及III期研究啓動

超長效TSLP靶向抗體HBM9378/WIN378在哮喘2期臨床取得積極結果，並啓動3期研究

苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會

勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股

智通财经网

禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准

【美股盤前】中東能源風險持續升温，布油逼近100美元，油氣股集體上漲，諾華製藥重挫13%

TradingKey中文

AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間

独角兽智库

康寧傑瑞製藥-B(09966)9月8日斥資184.99萬港元回購22萬股

IONIS製藥股價盤前下跌13.1%

每日经济新闻

道指期貨跌逾400點歐股早段窄幅向下瑞士諾華製藥挫9% 亞股普遍偏軟

阿斯达克财经

歌禮制藥-B(01672)在美國啓動口服胰澱素受體激動劑多肽ASC36 治療肥胖症的I期研究

石藥集團(01093.HK)：化藥創新藥SYH2083滴眼液在中國獲臨床試驗批准

諾華製藥（NVS）跌12.76% 多款在研藥接連遇阻

「底部整理+趨勢反彈」，開拓藥業-B(09939)何時站上估值反轉的關鍵節點？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=11"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":486.05957,"timestamp":1789617598991,"preClose":482.35672,"halted":0,"volume":32234011,"delay":0,"changeRate":0.007677,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午間休市","change":3.70285,"latestTime":"09-17 12:00:00","open":482.07187,"high":489.93134,"low":481.40475,"amount":762352440,"amplitude":0.017677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789621200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":3.604829,"peRate":160.310337,"turnoverRate":0.001226,"increases":19,"decrements":7,"flats":6,"marketCap":308982900176,"floatMarketCap":274602044232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.93134,"amplitude":0.017677,"preClose":482.35672,"low":481.40475,"pbRate":"3.604829","latestPrice":486.05957,"volume":32234011,"delay":0,"open":482.07187,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.758,"twentyDayClose":517.015,"sixtyDayClose":440.071,"secType":"PLATE","market":"HK","turnoverRate":0.001226,"peRate":160.310337,"marketCap":308982900176,"floatMarketCap":274602044232,"timestamp":1789617598991,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":19,"down":7,"flat":7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:11,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666305240","title":"2026國談第五日：商保創新藥目錄價格協商開始 多家藥企攜核藥、CAR-T新藥等重磅藥物進場","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305240","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305240?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 09:06","pubTimestamp":1788915970,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","06978","BK1161","MEDX","BK1574","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308479","title":"我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308479","media":"每日经济新闻","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308479?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 07:01","pubTimestamp":1788908468,"startTime":"0","endTime":"0","summary":"丨2026年9月9日星期三丨NO.1诺华制药DM1药物III期临床未达主要终点9月8日，诺华制药宣布，其评估del-desiran治疗1型强直性肌营养不良（DM1）的III期HARBOR研究未达到主要终点。公司表示，将进一步分析完整数据，并与监管机构沟通后确定后续开发路径。点评：消息放出后，诺华股价明显受挫，反映资本市场对该管线预期大幅下调。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093868484469.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093868484469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","IE00BFTCPJ56.SGD","BK0028","LU0211331839.USD","BK1515","300357","PPH","MEDX","BK4585","BK4578","BK4588","LU0070302665.USD","NVS","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4532","IE0002141913.USD","BK4007","LU0320765489.SGD","LU0208291251.USD","159938","IE00B2B36J28.USD","BK1161","IE00BJT1NW94.SGD","BK0239","BK1574","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666654371","title":"中藥創新從「經驗方」走到「數據方」","url":"https://stock-news.laohu8.com/highlight/detail?id=2666654371","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666654371?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 23:28","pubTimestamp":1788881280,"startTime":"0","endTime":"0","summary":"传统中药源于历代医家的经验积累，但面对现代医学的检验标准，如何用可重复、可量化的数据证明其安全性和有效性，始终是中药现代化进程中绕不开的一道题。近期，《证券日报》记者在梳理相关上市公司公告时注意到，有一个词被越来越多的中药企业频繁提及——循证医学。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868422064.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868422064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","MEDX","BK1574","BK4159","06978","LNGR","RCT","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665620376","title":"港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665620376","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665620376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:13","pubTimestamp":1788876780,"startTime":"0","endTime":"0","summary":"今日(9月8日)，港股市场整体震荡走弱，各大核心指数涨跌分化明显。截至收盘，恒生指数微跌0.38%，报25317.18点，单日下跌95.94点；国企指数同步小幅下行，跌幅0.38%，收报8397.32点；恒生科 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["07568","BK4585","09834","09086","159938","03455","09939","VGT","BK1161","XLK","VXUS","BK4588","TTTN","07261","KCAI","07266","BK1147","02834","03086","BK1574","BK1515","07522","03034"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376381","title":"諾華製藥(NVS)股票9月8日開盤下跌12.63%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376381","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376381?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:48","pubTimestamp":1788875309,"startTime":"0","endTime":"0","summary":"• 在 del-desiran 的 III 期 HARBOR 临床试验宣告失败后，诺华股价下跌。\n• pelacarsen 的心血管试验同样未能达到减少心血管事件的主要终点。\n• 多项研发管线遭遇挫折，加剧了投资者的审视，并推升了结构性增长风险。","market":"us","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156193-market-movers-nvs-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","NVS","LU0211331839.USD","BK4007","BK4578","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4588","IE0009355771.USD","BK4585","BK1191","IE00B4R5TH58.HKD","LU0320765489.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0208291251.USD","IE0002141913.USD","MEDX","BK4532","PPH","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665758793","title":"同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665758793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665758793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:23","pubTimestamp":1788873797,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司董事长、执行董事兼总裁吴豫生博士(吴博士)已告知本公司，吴博士近日于公开市场购买本公司股份，未来可能继续根据市场情况购买本公司股份，目前预计增持总金额不超过200万港元。吴博士已向本公司承诺，他在未来一个月内通过增持获得的本公司股份将分别自购入日起自愿锁定六个月，并在锁定期内不会出售或通过其他方式转让有关股份。吴博士表示，本次股份增持的资金来自其自有资金。此次增持股份彰显其对本集团未来发展前景的坚定信念及充分信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","02410","BK1515","BK1161","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665738153","title":"和鉑醫藥-B(02142)：HBM9378/WIN378治療哮喘的 II期臨床取得陽性的中期結果及III期研究啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665738153","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665738153?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:54","pubTimestamp":1788872083,"startTime":"0","endTime":"0","summary":"HBM9378/WIN378是目前已知唯一一款通过双位点结合TSLP来阻断其信号通路的在研药物，能够干扰TSLP与其两个共受体在上皮细胞表面的结合。该研究亦同时评估HBM9378/WIN378对肺功能和气道炎症生物标志物的影响。其III期部分正在评估两种每年两次给药剂量的HBM9378/WIN378对比安慰剂的疗效，主要终点为重度哮喘患者的年化哮喘急性发作率。HBM9378/WIN378耐受性及安全性良好，截至数据截止日期，未观察到治疗相关严重不良事件、退出或停药。注射部位反应发生率低于1%，抗药物抗体发生率为2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：HBM9378/WIN378治疗哮喘的 II期临床取得阳性的中期结果及III期研究启动","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111196658","title":"超長效TSLP靶向抗體HBM9378/WIN378在哮喘2期臨床取得積極結果，並啓動3期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1111196658","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111196658?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869898,"startTime":"0","endTime":"0","summary":"聚焦呼吸系统疾病治疗领域的重大突破——和铂医药-B旗下重磅在研产品HBM9378/WIN378，一种针对胸腺基质淋巴细胞生成素的超长效抗体，近日在哮喘适应症的2期临床试验中交出亮眼答卷，数据表现令人振奋。2期临床数据显示，HBM9378/WIN378在控制哮喘症状、改善肺功能等关键指标上均展现出具有临床意义的改善，安全性与耐受性同样可圈可点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378020","title":"苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378020","media":"证券日报 ","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:16","pubTimestamp":1788869760,"startTime":"0","endTime":"0","summary":"9月8日，苑东生物发布公告称，公司将于9月16日参加科创板2026年半年度创新药行业集体业绩说明会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688513","159992","KSTR","IBBQ","BK1574","MEDX","BK0239","06978","LNGR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665135320","title":"勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665135320","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665135320?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:09","pubTimestamp":1788869377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月8日，该公司斥资154.18万港元回购5.7万股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02595","BK1515","159938","BK1161","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准，将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知，AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性，并可在保留蛋白酶对IgA1高效切割活性的同时，显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性，为长效、低频次给药奠定基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","PSYK","09637","BK1574","IBBQ","159938","BMED","BK1161","159151","MDTX","IBBJ","BK1191","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320476","title":"【美股盤前】中東能源風險持續升温，布油逼近100美元，油氣股集體上漲，諾華製藥重挫13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320476","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320476?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868800,"startTime":"0","endTime":"0","summary":"TradingKey - 美东时间周二（9月8日），美股三大股指期货盘前涨跌不一。伊朗宣布将在波斯湾和阿曼湾实施新的限制措施，也门胡塞武装则袭击沙特能源设施，推动国际油价继续走高。能源价格上涨令通胀担忧重新升温，加上日元升至2月以来最高水平，市场风险偏好受到压制。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20240521/de7092af7e5b1e2c1a439a49d278289d.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20240521/de7092af7e5b1e2c1a439a49d278289d.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/analysis/stocks/us-stock/262155942-us-pre-market-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","NVS","LU0211331839.USD","BK4007","BK4578","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4588","UCO","UUP","IE0009355771.USD","BK4585","UDN","DBO","DUG","BK1191","IE00B4R5TH58.HKD","LU0320765489.SGD","159195","DWT","BK4570","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0208291251.USD","BZmain","IE0002141913.USD","USO","MEDX","BK4532","CLmain","DDG","SCO","PPH","159945","01477","QMmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320908","title":"AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320908","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:44","pubTimestamp":1788867840,"startTime":"0","endTime":"0","summary":"AI 制药行业已经走过早期概念炒作阶段，产业验证层级持续向上，从算法叙事正式转向管线价值兑现，行业商业化拐点正在加速到来。随着 AI 制药行业持续发展，生物测序数据需求持续扩张，设备与试剂业务打开增量空间，站在产业链上游充分受益行业整体景气上行。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-08/doc-inircmes6042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","LNGR","QTOC","ARTY","BK1161","BK1191","CHAT","BK1574","AGIX","MEDX","AIPO","VTHR","01477","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432730","title":"康寧傑瑞製藥-B(09966)9月8日斥資184.99萬港元回購22萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432730","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665432730?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:26","pubTimestamp":1788866778,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年9月8日斥资184.99万港元回购22万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322002","title":"IONIS製藥股價盤前下跌13.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322002","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322002?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:37","pubTimestamp":1788863820,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月8日，IONIS制药股价盘前下跌13.1%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-08/doc-inircmeu4524288.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-08/doc-inircmeu4524288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732107","title":"道指期貨跌逾400點  歐股早段窄幅向下  瑞士諾華製藥挫9%  亞股普遍偏軟","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732107","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732107?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:15","pubTimestamp":1788862500,"startTime":"0","endTime":"0","summary":"美股隔晚“劳动节”假期休市，美股三大指数期货分化，道指期货现跌401点或1.75%，报53,039点。标普500期货跌19点或0.25%、纳指期货微升4点或0.02%。欧洲主要股市周二早段全面窄幅向下，泛欧600指数跌0.2%，报648.8点。英国富时100指数微跌2点，报10,819点。德国DAX跌89点或0.3%，报25,917点。西班牙IBEX 35跌87点或0.4%，报19,934点。瑞士诺华制药急挫9%，其用于肌肉萎缩症的实验药物del-desiran在后期试验中失败。亚太区主要股市今日普遍偏软。韩股收跌40点或0.6%，报6,954点。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190703175731745_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190703175731745_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543449/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543449/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["FGBXmain","BK1191","YMmain","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665503321","title":"歌禮制藥-B(01672)在美國啓動口服胰澱素受體激動劑多肽ASC36 治療肥胖症的I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2665503321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665503321?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:04","pubTimestamp":1788861852,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，在近期获得美国食品药品监督管理局 批准新药临床试验后，其已启动ASC36口服片用于治疗肥胖症的美国I期研究。在非人灵长类动物中，ASC36口服片每日一次给药7天后，使平均体重相较基线下降高达13.2%。ASC36片亦显著减少了食物摄入。基于潜在更优的口服生物利用度和疗效，与近期获FDA批准的一款GLP-1R激动剂多肽相比，预计ASC36口服片的给药剂量更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1191","BK1161","01477","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665296783","title":"石藥集團(01093.HK)：化藥創新藥SYH2083滴眼液在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665296783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665296783?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:48","pubTimestamp":1788860890,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2039709279.SGD","LU0315179316.USD","BK1574","IE00B5MMRT66.SGD","LU0880133367.SGD","IE0008368742.USD","LU1008478684.HKD","06978","BK1515","LU1152091754.HKD","LU1807302812.USD","HK0000165453.HKD","LU1813983027.USD","LU1226288253.USD","BK1521","LU0140636845.USD","IE00B543WZ88.USD","KURE","01093","LU1951186391.HKD","BK1161","LU0501845795.SGD","LU1226288170.HKD","IE00B031HY20.USD","LU1152091168.USD","IE00BZ08YR35.GBP","LU1226287529.USD","IE0008369823.USD","SG9999004220.SGD","LU0072913022.USD","LU0067412154.USD","BK1191","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU0326950275.SGD","LU1226287792.SGD","LU1328277881.USD","LU0314109678.HKD","LU1226287875.USD","LU1960683339.HKD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325749","title":"諾華製藥（NVS）跌12.76% 多款在研藥接連遇阻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325749","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325749?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:48","pubTimestamp":1788857295,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药 美股盘前股价承压，最新跌12.76%，报139.5美元。消息面上，诺华制药一周内接连遭遇三项临床试验重大挫折。同样在上周，因出现三例患者死亡案例，诺华紧急叫停八项针对自身免疫、神经系统疾病的CAR-T疗法临床试验。死亡原因指向严重免疫反应，诺华表示该类风险属于CAR-T疗法已知安全隐患，目前正开展全面安全核查，同步配合独立安全委员会工作，并向监管机构报送相关信息，死亡事件具体发生时间尚未对外披露。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305795","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPH","BK4585","IE00BJT1NW94.SGD","BK1191","IE0002141913.USD","IE00BJJMRZ35.SGD","BK1574","NVS","BK4007","01477","IE00BFTCPJ56.SGD","LU0208291251.USD","BK4578","IE0009355771.USD","LU0320765489.SGD","IE00B2B36J28.USD","LU0070302665.USD","IE00B4R5TH58.HKD","MEDX","LU0211331839.USD","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932548","title":"「底部整理+趨勢反彈」，開拓藥業-B(09939)何時站上估值反轉的關鍵節點？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932548?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:43","pubTimestamp":1788856994,"startTime":"0","endTime":"0","summary":"9月7日盘前，开拓药业-B发布公告，宣布其自主研发的抑制黑色素生成的新型高效酪氨酸酶抑制剂KT-939的人体长期安全性试验已于2026年9月4日顺利结束。初步数据显示，合计114位受试者连续52周使用KT-939后，未出现皮肤不良反应，且与该试验中期28周临床使用结果一致，充分展现了KT-939具有良好的安全性。在该利好消息刺激下，开拓药业股价当日开盘后迅速走高，半小时内涨幅拉升至9.89%，股价再次站上2港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":11,"totalSize":331,"code":"91000000","status":"200"}]}}